28th Nov 2013 14:46
LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday that a two-dose schedule of its cervical cancer vaccine Cevarix has been recommended for market authorisation by the European Medicines Agency's Committee for Medicinal Products For Human Use.
This is one of the final steps towards the product being granted marketing authorisation by the European Commission, although Glaxo stressed that it does not always result in marketing authorisation.
The vaccine, intended for use for females between the age of nine and fourteen, is already approved in the EU on a three-dose schedule. Glaxo said a three-dose schedule is still recommended for girls and women over fifteen.
Shares in Glaxo were trading up 0.50 pence at 1,615.50p Thursday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline